glp-1 inhibitor drugs New Guidelines for Type 2 Diabetes in 2025 What to Make of the

While peptide drugs have a wide range of therapeutic applications, their relatively short half-life has been a challenge, attributed to poor metabolic stability and a fluid dynamic radius below the glomerular filtration limit of the kidneys.

WHO GLP-1 Treatments: The World Health Organization has issued new guidelines endorsing GLP-1 agonists as essential treatments for obesity, highlighting the urgent need for action against the rising global obesity epidemic affecting over one billion people and posing serious health risks.

Despite these findings, a clear link has yet to be established, and much of the evidence remains inconsistent

Pfizer's obesity pill danuglipron has not progressed to Phase 3 trials and is not approved in the UK

Considerations for employers who are thinking about covering GLP-1 drugs for weight loss.